Table 1.
Main clinical characteristics and biological data of the total population of the study and according to antivitamin K (VKA) therapy status
| Total population | Non-treated with VKA | Treated with VKA | P (between treated and non-treated) | |
|---|---|---|---|---|
| n | 160 | 137 | 23 | |
| Age (yr) | 74 [63; 80] | 74 [64; 81] | 71 [59; 79] | NS |
| Male gender (%) | 44 | 43 | 52 | NS |
| Body mass index (kg/m2) | 25.4 [22.6; 30.2] | 25.4 [22.6; 30.2] | 27.3 [24.7; 33.3] | NS |
| Dialysis vintage (month) | 23 [11; 44] | 22 [11; 48] | 24 [13; 38] | NS |
| Previous CVD (%) | 65 | 64 | 74 | NS |
| Hypertension (%) | 87 | 85 | 100 | 0.046 |
| Diabetes (%) | 44 | 43 | 52 | NS |
| Smoking habit (%) | 21 | 21 | 22 | NS |
| Calcium (mmol/L) | 2.15 ± 0.16 | 2.16 ± 0.15 | 2.14 ± 0.20 | NS |
| Phosphate (mg/dL) | 4.6 [4.0; 6.0] | 4.6 [4; 6] | 5.1 [4.3; 5.7] | NS |
| Albumin (g/L) | 38 [36; 40] | 38 [36; 40] | 40 [38; 40] | NS |
| CRP (mg/L) | 5 [2; 13] | 5 [2; 13] | 4 [3; 9] | NS |
| Intact PTH (pg/mL) | 263 [126; 434] | 251 [129; 423] | 291 [125; 570] | NS |
| 25-OH vitamin D (ng/mL) | 22 [12; 33] | 22 [12; 33] | 19 [13; 25] | NS |
| b-ALP (μg/L) | 16 [11; 23] | 15 [10; 23] | 19 [13; 29] | NS |
| FGF-23 (RU/mL) | 2911 [1039; 7413] | 2733 [883; 7597] | 3179 [2391; 6676] | NS |
| Calcification score (maximum score is 24) | 10 [5; 15] | 10 [5; 15] | 11 [6; 17] | NS |
| dp-ucMGP (pmol/L) | 2148 [1542; 3251] | 1939 [1419; 2841] | 5604 [3758; 7836] | <0.0001 |
Note: conversion factor for units: phosphorus in mg/dL to mmol/L, x0.3229. Data are expressed as mean ± standard deviation (SD) when distribution was normal and as median and interquartile range [percentile 25; percentile 75] when not. CVD, cardiovascular disease; CRP, C-reactive protein; PTH, parathormone; b-ALP bone-specific alkaline phosphatase; dp-ucMGP, dephosphorylated and uncarboxylated; NS, non significant (p > 0.05).